Cardiac Biomarkers and Left Ventricular Hypertrophy in Asymptomatic Hemodialysis Patients

  • Reneta Yovcheva Koycheva Department of Nephrology, University Hospital "Prof. Dr. Stoyan Kirkovich", Stara Zagora
  • Vasil Cholakov Department of Nephrology, University Hospital "Prof. Dr. Stoyan Kirkovich", Stara Zagora
  • Jivko Andreev Department of Nephrology, University Hospital "Prof. Dr. Stoyan Kirkovich", Stara Zagora
  • Margarit Penev Department of Nephrology, University Hospital "Prof. Dr. Stoyan Kirkovich", Stara Zagora
  • Rosen Iliev Department of Nephrology, University Hospital "Prof. Dr. Stoyan Kirkovich", Stara Zagora
  • Krasimira Nancheva Department of Nephrology, University Hospital "Prof. Dr. Stoyan Kirkovich", Stara Zagora
  • Vanya Tsoneva Department of Nephrology, University Hospital "Prof. Dr. Stoyan Kirkovich", Stara Zagora
Keywords: hemodialysis, cardiac troponin T, natriuretic peptide, C-reactive protein, left ventricular hypertrophy

Abstract

BACKGROUND: Cardiac biomarkers are often elevated in dialysis patients showing the presence of left ventricular dysfunction. The aim of the study is to establish the plasma levels of high-sensitivity cardiac troponin T (hs TnT), precursor of B-natriuretic peptide (NT-proBNP) and high sensitivity C-reactive protein (hs CRP) and their relation to the presence of left ventricular hypertrophy (LVH) in patients undergoing hemodialysis without signs of acute coronary syndrome or heart failure.

MATERIAL AND METHODS: Were studied 48 patients - 26 men and 22 women. Pre and postdialysis levels of hs cTnT, NT-proBNP and hs CRP were measured at week interim procedure. Patients were divided in two groups according to the presence of echocardiographic evidence of LVH - gr A - 40 patients (with LVH), and gr B - 8 patients (without LVH).

RESULTS: In the whole group of patients was found elevated predialysis levels of all three biomarkers with significant increase (p < 0.05) after dialysis with low-flux dialyzers. Predialysis values of NT-proBNP show moderate positive correlation with hs cTnT (r = 0.47) and weaker with hs CRP (r = 0.163). Such dependence is observed in postdialysis values of these biomarkers. There is a strong positive correlation between the pre and postdialysis levels: for hs cTnT (r = 0.966), for NT-proBNP (r = 0.918) and for hs CRP (r = 0.859). It was found a significant difference in the mean values of hs cTnT in gr. A and gr. B (0.07 ± 0.01 versus 0.03 ± 0.01 ng /mL, p < 0.05) and NT-proBNP (15,605.8 ± 2,072.5 versus 2,745.5 ± 533.55 pg /mL, p < 0.05). Not find a significant difference in hs CRP in both groups.

CONCLUSIONS: The results indicate the relationship of the studied cardiac biomarkers with LVH in asymptomatic patients undergoing hemodialysis treatment.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Zoccali C, Benedetto FA, Mallamaci F, et al. Left ventricular mass monitoring in the follow-up of dialysis patients: Prognostic value of left ventricular hypertrophy progression. Kidney Int. 2004;65:1492–1498.

http://dx.doi.org/10.1111/j.1523-1755.2004.00530.x

PMid:15086493

Parfrey PS, Collingwood P, Foley RN, Bahrle A. Left ventricular disorders detected by M-mode echocardiography in chronic uremia. Nephrol Dial Transplant. 1996;11:1328-1331.

http://dx.doi.org/10.1093/ndt/11.7.1328

PMid:8672032

Harnett JD, Murphy B, Collingwood P, Purchase L, Kent G, Parfrey PS. The reliability and validity of echocardiographic measurement of left ventricular mass index in hemodialysis patients. Nephron. 1993;65:212-214.

http://dx.doi.org/10.1159/000187476

PMid:8247182

Harnett JD, Kent GM, Barre PE, et al. Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J Am Soc Nephrol. 1994;4:1486-1490.

PMid:8161730

Parfrey PS, Griffiths SM, Harnett JD, et al. Outcome of congestive heart failure, dilated cardiomyopathy, hypertrophic hyperkinetic disease and ischemic heart disease in dialysis patients. Am J Nephrol. 1990;10:213-221.

http://dx.doi.org/10.1159/000168084

PMid:2143353

Parfrey PS, Foley RN, Harnett JD, et al. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant. 1996;11:1277-1285.

http://dx.doi.org/10.1093/ndt/11.7.1277

PMid:8672023

Ritz E, Wanner C. The challenge of sudden death in dialysis patients. Clin J Am Soc Nephrol. 2008;3:920-929.

http://dx.doi.org/10.2215/CJN.04571007

PMid:18372318

Gross ML, Ritz E. Hypertrophy and fibrosis in the cardiomyopathy of uremia - beyond coronary heart disease. Semin Dial. 2008;21:308-318.

http://dx.doi.org/10.1111/j.1525-139X.2008.00454.x

PMid:18627569

Ritz E. Left ventricular hypertrophy in renal disease: beyond preload and afterload. Kidney Int. 2009;75:771-773.

http://dx.doi.org/10.1038/ki.2009.35

PMid:19337217

Steigerwalt S, Zafar A, Mesiha N, Gardin J, Provenzano R. Role of aldosterone in left ventricular hypertrophy among African-American patients with end-stage renal disease on hemodialysis. Am J Nephrol. 2007;27:159-163.

http://dx.doi.org/10.1159/000100106

PMid:17317951

Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47:186-192.

http://dx.doi.org/10.1038/ki.1995.22

PMid:7731145

Cerasola G, Nardi E, Palermo A, et al. Epidemiology and pathophysiology of left ventricular abnormalities in chronic kidney disease: a review. J Nephrol. 2011;24:1-10.

http://dx.doi.org/10.5301/JN.2010.2030

PMid:20437402

Xu X, Hu X, Zhang P, Zhao L, Wessale JL. Bache RJ. Chen Y: Xantine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice. J Card Fail. 2008;14:746-753.

http://dx.doi.org/10.1016/j.cardfail.2008.06.006

PMid:18995179 PMCid:PMC2610415

Martin LC, Franco RJ, Gavras I, Matsubara BB, Garcia S, Caramori JT, Barretti BB, Balbi AR, Barsanti R, Padovani C, Gavras H. Association between hypervolemia and ventricular hypertrophy in hemodialysis patients. Am J Hypertens. 2004;17:1163-1169.

http://dx.doi.org/10.1016/j.amjhyper.2004.07.017

PMid:15607624

McRae JM, Levin A, Belenkie I. The cardiovascular effects of arteriovenous fistulas in chronic kidney disease. A cause for concern? Semin Dial. 2006;19:349-352.

http://dx.doi.org/10.1111/j.1525-139X.2006.00185.x

PMid:16970729

Nishida K, Kyoi S, Yamaguchi O, Sadoshima J, Otsu K. The role of autophagy in the heart. Cell Death Differ. 2009;16:31-38.

http://dx.doi.org/10.1038/cdd.2008.163

PMid:19008922

Dorm GW 2nd: Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodeling. Cardiovasc Res. 2009;81:465-473.

http://dx.doi.org/10.1093/cvr/cvn243

PMid:18779231 PMCid:PMC2721651

Zoccali C, Benedetto FA, Tripepi G, Mallamaci F. Cardiac consequences of hypertension in hemodialysis patients. Semin Dial. 2004;17:299-303.

http://dx.doi.org/10.1111/j.0894-0959.2004.17331.x

PMid:15250922

Steigerwalt S, Zafar A, Mesiha N, Gardin J, Provenzano R. Role of aldosterone in left ventricular hypertrophy among African-American patients with end-stage renal disease on hemodialysis. Am J Nephrol. 2007;27:159-163.

http://dx.doi.org/10.1159/000100106

PMid:17317951

Sakurabayashi T, Miyazaki S, Yuasa Y, Sakai S, Suzuki M, Takahashi S, Hirasawa Y. L-Carnitine supplementation decreases the left ventricular mass in patients undergoing hemodialysis. Circ J. 2008;72: 926-931.

http://dx.doi.org/10.1253/circj.72.926

PMid:18503218

Strozecki P, et al. Parathormon. calcium. phosphorus and left ventricular structure and function in normotensive hemodialysis patients. Ren Fail. 2001;23:115-126.

http://dx.doi.org/10.1081/JDI-100001291

PMid:11256521

Di Lullo L, Floccari F, Polito P. Right ventricular diastolic function in dialysis patients could be affected by vascular access. Nephron Clin Pract. 2011;118:c258-c262.

http://dx.doi.org/10.1159/000321867

PMid:21196771

Kim BS, Jeon DS, Shin MJ, et al. Persistent elevation of C-reactive protein may predict cardiac hypertrophy and dysfunction in patients maintained on hemodialysis. Am J Nephrol. 2005;25:189-195.

http://dx.doi.org/10.1159/000085585

PMid:15863980

Felker GM, Petersen JW, Mark DB. Natriuretic peptides in the diagnosis and management of heart failure. CMAJ. 2006;175:611-7.

http://dx.doi.org/10.1503/cmaj.060236

PMid:16966666 PMCid:PMC1559415

Goetze JP, Christoffersen C, Perko M, et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J. 2003;17:1105-7.

http://dx.doi.org/10.1096/fj.02-0796fje

Konstam MA. Natriuretic peptides and cardiovascular events: More than a stretch. JAMA. 2007;297:212-4.

http://dx.doi.org/10.1001/jama.297.2.212

PMid:17213406

Sullivan DR, West M, Jeremy R. Utility of brain natriuretic peptide (BNP) measurement in cardiovascular disease. Heart Lung Circ. 2005;14:78-84.

http://dx.doi.org/10.1016/j.hlc.2005.03.002

PMid:16352258

Codognotto M, Piccoli A, Zaninotto M, et al. Effect of a dialysis session on the prognostic values of NT-proBNP, troponins, endothelial damage and inflammation biomarkers. J Nephrol. 2010;23:465-71.

PMid:20540041

Heeschen C, Deu A, Langenbrink L, Goldmann BU, Hamm CW. Analytical and diagnostic performance of troponin assays in patients suspicious for acute coronary syndromes. Clin Biochem. 2000;33:359-368.

http://dx.doi.org/10.1016/S0009-9120(00)00144-2

Resić H, Ajanović S, Kukavica N, et al. Plasma levels of brain natriuretic peptides and cardiac troponin in hemodialysis patients. Bosnian Journal of basic medical sciences. 2009;9:137-141.

PMid:19485946

Dervisoglu E, Kozdag G, Etiler N, Kalender B. Association of glomerular filtration rate and inflammation with left ventricular hypertrothy in chronic kidney disease patients. Hippokratia. 2012;16:137-142.

PMid:23935269 PMCid:PMC3738415

Paoletti E, Bellino D, Cassottana P, et al. Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis. 2005;46:320-327.

http://dx.doi.org/10.1053/j.ajkd.2005.04.031

PMid:16112052

Mahmud A, Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension. 2005;46:1118-1122.

http://dx.doi.org/10.1161/01.HYP.0000185463.27209.b0

PMid:16216991

Ratto E, Leoncini G, Viazzi F, et al. C-reactive protein and target organ damage in untreated patients with primary hypertension. J Am Soc Hypertens. 2007;1:407- 413.

http://dx.doi.org/10.1016/j.jash.2007.09.003

PMid:20409873

Wahl HG, Graf S, Renz H, Fassbinder W. Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis. Clin Chem. 2004;50: 1071–1074.

http://dx.doi.org/10.1373/clinchem.2003.030692

PMid:15161726

Roongsritong C, Warraich I, Bradley C. Common causes of troponin elevations in the absence of acute myocardial infarction: incidence and clinical significance. Chest. 2004;125:1877–1884.

http://dx.doi.org/10.1378/chest.125.5.1877

PMid:15136402

Saunders JT, Nambi V, de Lemos JA, et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation. 2011;123:1367–1376.

http://dx.doi.org/10.1161/CIRCULATIONAHA.110.005264

PMid:21422391 PMCid:PMC3072024

Wallace TW, Abdullah SM, Drazner MH, et al. Prevalence and determinants of troponin T elevation in the general population. Circulation. 2006;113:1958–1965.

http://dx.doi.org/10.1161/CIRCULATIONAHA.105.609974

PMid:16618821

Wang AY, Lai KN. Use of cardiac biomarkers in end-stage renal disease. J Am Soc Nephrol. 2008;19:1643–1652.

http://dx.doi.org/10.1681/ASN.2008010012

PMid:18322158

Published
2015-12-30
How to Cite
1.
Koycheva RY, Cholakov V, Andreev J, Penev M, Iliev R, Nancheva K, Tsoneva V. Cardiac Biomarkers and Left Ventricular Hypertrophy in Asymptomatic Hemodialysis Patients. Open Access Maced J Med Sci [Internet]. 2015Dec.30 [cited 2020Dec.5];4(1):59-4. Available from: https://www.id-press.eu/mjms/article/view/oamjms.2016.011
Section
B - Clinical Sciences